Zepbound Geriatric (65+): School and Activity Considerations

Does the Zepbound label treat patients 65 and older differently?

The dosing section gives every adult the same escalation: 2.5 mg once weekly for 4 weeks, then 5 mg, with further 2.5 mg steps after at least 4 weeks on the current dose, reaching maintenance doses of 5, 10 or 15 mg weekly and a maximum of 15 mg [1]. The 2.5 mg dose is for starting only and is not a maintenance dose [1]. The label calls for no dose adjustment in renal or hepatic impairment [1].

The labeled uses are weight reduction and long-term weight maintenance in adults with obesity or overweight plus a weight-related condition, and treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, in combination with a reduced-calorie diet and increased physical activity [1]. The pooled weight-management trials had a mean age of 47 years [1].

What the label lists that can affect activity

• Dizziness: 4%, 5% and 4% at 5, 10 and 15 mg versus 2% with placebo [1].
• Fatigue: 5%, 6% and 7% versus 3% with placebo [1].
• Low blood pressure: hypotension 1.6% versus 0.1% with placebo, and 2.2% in patients also taking antihypertensive drugs versus 1.2% in those who were not [1].
• Stomach and bowel effects: any gastrointestinal adverse reaction in 56% at every Zepbound dose versus 30% with placebo; most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]. Severe gastrointestinal reactions occurred in 1.7%, 2.5% and 3.1% versus 1% with placebo [1].
• Dehydration: acute kidney injury from volume depletion has been reported, mostly after gastrointestinal reactions; the label says to monitor renal function in patients with such reactions, especially during initiation and dose escalation [1].
• Low blood sugar: risk increases with insulin or an insulin secretagogue, and the label says to consider reducing the insulin or secretagogue dose when starting Zepbound [1].
• Procedures: pulmonary aspiration during general anesthesia or deep sedation has been reported with GLP-1 receptor agonists, and the label tells patients to inform healthcare providers of any planned surgery or procedure [1].
• Pen handling: the KwikPen is not recommended for self-administration by people who are visually impaired, and a pen must never be shared between patients, even with a new needle [1].

Muscle mass: what the body-composition substudy measured

A substudy of SURMOUNT-1 measured body composition with DXA at baseline and at week 72 in 160 participants: 124 pooled across the tirzepatide doses and 36 on placebo, 73% female, mean weight 102.5 kg and BMI 38.0 [2]. Over 72 weeks, body weight changed by -21.3% with tirzepatide versus -5.3% with placebo, fat mass by -33.9% versus -8.2%, and lean mass by -10.9% versus -2.6% (p<0.001 for each comparison) [2].

Of the weight lost, roughly 75% was fat mass and 25% lean mass in both the tirzepatide and placebo groups. Post hoc subgroups were defined by sex, by age (under 50, 50 to under 65, and 65 and older) and by weight-loss tertile, and the proportions remained consistent across most of them [2]. The substudy was small, and DXA cannot separate muscle from other lean tissue [2]. The label's own wording is that tirzepatide lowers body weight with greater fat mass loss than lean mass loss, and it gives no lean-mass numbers [1].

Exercise, classes and fall prevention

The DXA substudy measured body composition, not strength, balance or falls [2]. A 2024 review of obesity drugs in older adults says that trials in this group should measure geriatric endpoints such as muscle-mass preservation, bone quality and fat distribution, rather than weight alone [3].

School, classes and lifelong learning

Cognitive, memory and attention effects are not listed among the warnings or common adverse reactions in the Zepbound label [1]. The adverse reactions reported in 5% or more of patients are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss and gastroesophageal reflux disease [1]. A lecture series, community class or online course may be harder during symptoms such as nausea, fatigue or dizziness [1].

What to watch for

The boxed warning covers thyroid C-cell tumors: in rats tirzepatide caused dose- and duration-dependent thyroid C-cell tumors, and whether it causes them in humans, including medullary thyroid carcinoma, is unknown [1]. Zepbound is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2, and the label advises counseling patients about symptoms of thyroid tumors such as a neck mass, difficulty swallowing, shortness of breath or persistent hoarseness [1]. The label says that if serious hypersensitivity is suspected, patients should promptly seek medical attention and Zepbound should be discontinued, and that it should also be discontinued if pancreatitis is suspected, with persistent severe abdominal pain sometimes radiating to the back as a signal [1]. Acute gallbladder disease is another listed risk, with cholecystitis in 0.7% versus 0.2% on placebo [1].

Stopping treatment and weight regain

In SURMOUNT-4, 783 adults received open-label tirzepatide 10 or 15 mg for 36 weeks; the 670 who were then randomized had lost a mean 20.9% of body weight and either continued tirzepatide or switched to placebo for 52 weeks [4]. From week 36 to week 88, weight changed by -5.5% with continued tirzepatide and +14.0% after the switch to placebo, a difference of 19.4 percentage points [4].